-PTI German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week. Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company’s decision to cut the price of the life-extending kidney and liver cancer drug “is a clear...
More »SEARCH RESULT
A healthier India: Need to resolve conflict between drug price controls, innovation and affordable healthcare-David Taylor
The debate about essential-medicine pricing and access in India illustrates the difficulties inherent in establishing policies that serve conflicting public interests in achieving goals such as caring well and ensuring safety for all, while also pursuing financially-sustainable success in scientific innovation and trade. It highlights problems facing those interested in continuing drug and vaccines development and ensuring that, once marketed, such products contribute effectively to improving public health. Modern pharmaceuticals...
More »Untreated groundwater a serious health issue, says survey-Aarti Dhar
A survey of 71 cities across the country conducted by the Centre for Science and Environment (CSE) has shown that officially 82 per cent of all the water that municipalities of these cities supply comes from surface water resources, and the rest comes from groundwater resources. But of these 71 cities, 11 depend almost completely on groundwater for public water supply. In the remaining, agencies supply water from surface sources by...
More »Glaring gender bias ails heart health-Kounteya Sinha
Women in India face discrimination even when it comes to their heart health. Three separate studies - one of them from India and the other two from China and West Asia - presented at the World Congress of Cardiology in Dubai on Friday said that women don't receive the same treatment as men for heart disease across the world. They said that women with acute coronary syndrome (ACS) receive inferior or less...
More »Patent to plunder -Amit Sengupta
India's efforts to produce and supply life-saving drugs at affordable prices face challenges from multinational companies trying to “evergreen” their patents. THE average life expectancy across the globe has increased from around 30 years a century ago to over 65 years today. This has been made possible in large part by modern medicine. Never before in history have humans had access to such an array of medicines and devices to...
More »